ATG101

Across TCGA pan-cancer cohorts, ATG101 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATG101 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATG101 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATG101 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ATG101 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.381	0.777	<.001	55	view →
PDAC	OS	Quartile	II,III,IV	0.519	0.812	.023	12	view →
LUAD	DFS	Median	II,III,IV	0.628	0.357	.016	6	view →
LSCC	DFS	Tertile	All	0.906	0.703	.025	6	view →
HNSC	DFS	Quartile	III,IV	1.000	0.849	.013	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATG101–CCRCC (DFS)

Open the CCRCC breakdown →